{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:28:00Z","timestamp":1772944080194,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12185-025-04138-2","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T13:00:41Z","timestamp":1766408441000},"page":"453-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mantle cell lymphoma exhibiting repeated progression with the initiation of a JAK-1 inhibitor for psoriatic arthritis"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-6321","authenticated-orcid":false,"given":"Tsugumi","family":"Satoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"4138_CR1","unstructured":"Board WCoTE. Haematolymphoid tumours: who classification of tumours, 5th Edition, Vol 11: WHO press; 2024."},{"key":"4138_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","volume":"132","author":"Y Natkunam","year":"2018","unstructured":"Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JKC, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132:1871\u20138.","journal-title":"Blood"},{"key":"4138_CR3","volume-title":"Lymphoma","author":"M Shibusawa","year":"2021","unstructured":"Shibusawa M, Kidoguchi K, Tanimoto T. Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders. In: Gallamini A, Juweid M, editors. Lymphoma. Brisbane (AU): Exon Publications; 2021."},{"key":"4138_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/JLB.5RU0519-145R","volume":"106","author":"E Gremese","year":"2019","unstructured":"Gremese E, Alivernini S, Tolusso B, Zeidler MP, Ferraccioli G. Jak inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J Leukoc Biol. 2019;106:1063\u20138.","journal-title":"J Leukoc Biol"},{"key":"4138_CR5","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Rheumatology (Oxford). 2021;60:ii24\u201330.","journal-title":"Rheumatology (Oxford)"},{"key":"4138_CR6","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"4138_CR7","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, den Van Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"4138_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.25259\/IJDVL_8_2023","volume":"89","author":"SP Raychaudhuri","year":"2023","unstructured":"Raychaudhuri SP, Raychaudhuri SK. Jak inhibitor: introduction. Indian J Dermatol Venereol Lepr. 2023;89:688\u201390.","journal-title":"Indian J Dermatol Venereol Lepr"},{"key":"4138_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83:760\u201374.","journal-title":"Ann Rheum Dis"},{"key":"4138_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5414\/CP204372","volume":"61","author":"R Inose","year":"2023","unstructured":"Inose R, Nakamura A, Omi R, Takeno S, Muraki Y. Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: a study based on a Japanese medical claims database. Int J Clin Pharmacol Ther. 2023;61:430\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4138_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/14397595.2021.1899570","volume":"32","author":"H Takada","year":"2022","unstructured":"Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, et al. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study. Mod Rheumatol. 2022;32:32\u201340.","journal-title":"Mod Rheumatol"},{"key":"4138_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/14397595.2020.1869370","volume":"32","author":"S Honda","year":"2022","unstructured":"Honda S, Sakai R, Inoue E, Majima M, Konda N, Takada H, et al. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study. Mod Rheumatol. 2022;32:16\u201323.","journal-title":"Mod Rheumatol"},{"key":"4138_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"4138_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:421\u20139.","journal-title":"JAMA Dermatol"},{"key":"4138_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","volume":"11","author":"A Rubbert-Roth","year":"2024","unstructured":"Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, et al. Malignancy in the Upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11:97\u2013112.","journal-title":"Rheumatol Ther"},{"key":"4138_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11739-015-1270-0","volume":"11","author":"M Fant\u00f2","year":"2016","unstructured":"Fant\u00f2 M, Peragallo MS, Pietrosanti M, Di Rosa R, Picchianti Diamanti A, Salemi S, et al. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med. 2016;11:31\u201340.","journal-title":"Intern Emerg Med"},{"key":"4138_CR17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.38385","volume":"66","author":"RL Gross","year":"2014","unstructured":"Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthrit Rheumatol. 2014;66:1472\u201381.","journal-title":"Arthrit Rheumatol"},{"key":"4138_CR18","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00277-020-04218-9","volume":"99","author":"H Katsuya","year":"2020","unstructured":"Katsuya H, Kizuka-Sano H, Yokoo M, Kidoguchi K, Yamaguchi K, Nishioka A, et al. A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH\/CCND1 translocation. Ann Hematol. 2020;99:2449\u201351.","journal-title":"Ann Hematol"},{"key":"4138_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/ncponc1071","volume":"5","author":"H Tran","year":"2008","unstructured":"Tran H, Cheung C, Gill D, Dua U, Nourse J, Boyle R, et al. Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. Nat Clin Pract Oncol. 2008;5:234\u20138.","journal-title":"Nat Clin Pract Oncol"},{"key":"4138_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000204120","volume":"93","author":"S Bilgrami","year":"1995","unstructured":"Bilgrami S, Shafi N, Pesanti EL, Ciesielski T, Singh NT, Chen LL, et al. Mantle-cell lymphoma in a patient with human immunodeficiency viral infection. Acta Haematol. 1995;93:101\u20134.","journal-title":"Acta Haematol"},{"key":"4138_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/bjh.18493","volume":"199","author":"R Bertinchamp","year":"2022","unstructured":"Bertinchamp R, Garzaro M, Boutboul D, Galicier L, Meignin V, Calvani J, et al. Mantle cell lymphoma in human immunodeficiency virus-infected patients. Br J Haematol. 2022;199:782\u20134.","journal-title":"Br J Haematol"},{"key":"4138_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","volume":"22","author":"H Tran","year":"2008","unstructured":"Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22:261\u201381.","journal-title":"Blood Rev"},{"key":"4138_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/2326-6066.CIR-16-0233","volume":"5","author":"SA Curran","year":"2017","unstructured":"Curran SA, Shyer JA, St Angelo ET, Talbot LR, Sharma S, Chung DJ, et al. Human dendritic cells mitigate NK-cell dysfunction mediated by nonselective JAK1\/2 blockade. Cancer Immunol Res. 2017;5:52\u201360.","journal-title":"Cancer Immunol Res"},{"key":"4138_CR24","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"K Sch\u00f6nberg","year":"2015","unstructured":"Sch\u00f6nberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187\u201399.","journal-title":"Cancer Res"},{"key":"4138_CR25","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.4049\/jimmunol.163.8.4109","volume":"163","author":"F Fallarino","year":"1999","unstructured":"Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999;163:4109\u201313.","journal-title":"J Immunol"},{"key":"4138_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1084\/jem.20020509","volume":"199","author":"T Nishibori","year":"2004","unstructured":"Nishibori T, Tanabe Y, Su L, David M. Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med. 2004;199:25\u201334.","journal-title":"J Exp Med"},{"key":"4138_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.13519","volume":"171","author":"C Keohane","year":"2015","unstructured":"Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, et al. JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171:60\u201373.","journal-title":"Br J Haematol"},{"key":"4138_CR28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192\u2013202.","journal-title":"Blood"},{"key":"4138_CR29","volume":"16","author":"S Oshima","year":"2024","unstructured":"Oshima S, Inano S, Kitano T. Epstein-Barr-virus-related lymphoproliferative disorder in a patient with primary myelofibrosis: a case report and literature review. Cureus. 2024;16:e56586.","journal-title":"Cureus"},{"key":"4138_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood. 2018;132:694\u2013706.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04138-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04138-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04138-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:10:52Z","timestamp":1772889052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04138-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4138"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04138-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TM is one of the editors of International Journal of Hematology. The remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}